CWP
PEAR

Concord Wealth Partners’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Concord Wealth Partners’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,000
Closed -$13K – 1266
2022
Q4 		$13K Buy
11,000
+1,000
+10% +$2.1K ﹤0.01% 600
2022
Q3 		$20K Buy
10,000
+3,000
+43% +$5.09K 0.01% 159
2022
Q2 		$11K Buy
7,000
+2,000
+40% +$7.82K ﹤0.01% 679
2022
Q1 		$25K Buy
5,000
+4,000
+400% +$18.2K 0.01% 592
2021
Q4 		$6K Buy
+1,000
New +$8.93K ﹤0.01% 921

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Concord Wealth Partners's PEAR Position: Q1 2023 in Review

Concord Wealth Partners sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q1 2023, closing a stake of 11,000 shares — an estimated $13K sold.

Concord Wealth Partners first reported a position in PEAR in Q4 2021 and held it in 5 quarters. The position peaked at $25K in Q1 2022. 53 funds tracked by Wall St. Rank hold PEAR as of Q1 2023.

  • Concord Wealth Partners reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q1 2023 after selling out during the quarter.
  • Concord Wealth Partners sold 11,000 Pear Therapeutics, Inc. Class A Common Stock shares in Q1 2023, an estimated $13K.
  • Concord Wealth Partners first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 5 quarters.
  • Concord Wealth Partners's Pear Therapeutics, Inc. Class A Common Stock position peaked at $25K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q1 2023.

Based on Concord Wealth Partners's 13F filing for Q1 2023, filed 26 Apr 2023.